Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.

AAPS pharmSci - 1 Jan 2000

McElroy S, Sachse C, Brockmoller J, Richmond J, Lira M, Friedman D, Roots I, Silber B M, Milos P M

Abstract excerpt

The emerging application of pharmacogenomics in the clinical trial setting requires careful comparison with more traditional phenotyping methodologies, particularly in the drug metabolism area where phenotyping is used extensively. The research objectives of this study were 1) to assess the utility of cytochrome P450 2D6 (CYP2D6) genotyping as an alternative to traditional phenotyping as a predictor of poor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Debrisoquin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dextromethorphan

Share to Genotype

Share to Pharmacogenetics and Drug Metabolism

Share to Phenotype

Share to Polymerase Chain Reaction

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 11741249
DOI: 10.1208/ps020433
PMCID: PMC2751283

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting.PMID 11741249Read ↗

Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships.Semantic proximity Read ↗

Identification and characterization of CYP2D6*56B, an allele associated with the poor metabolizer phenotype.Semantic proximity Read ↗

Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians.Semantic proximity Read ↗

Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity.Semantic proximity Read ↗

Cytochrome P450 2D6 polymorphism in eastern Indian population.Semantic proximity Read ↗

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.Semantic proximity Read ↗

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.Semantic proximity Read ↗

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry.Semantic proximity Read ↗

Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.Semantic proximity Read ↗

In vivo characterization of CYP2D6*12, *29 and *84 using dextromethorphan as a probe drug: a case report.Semantic proximity Read ↗

Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.Semantic proximity Read ↗

The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.